drugset / Trial / NCT01735240

Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.

NCT01735240

Phase 1 Completed 15 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The main purpose of the study is to compare the change of the AZD5069 Pharmacokinetic profile when administered with ketoconazole. Subjects will be treated first with AZD5069 only followed by a washout period before starting with the combined treatment (both ketoconazole and AZD5069).

Timeline

Start
2012-12
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5069 Small molecule 15 mg Oral
Subject Ketoconazole Small molecule 400 mg

Indications